Motloch, L.J.,
Larbig, R.,
Darabi, T.,
Reda, S.,
Motloch, K.A.,
Wernly, B.,
Lichtenauer, M.,
Gebing, T.,
Schwaiger, A.,
Zagidullin, N.,
Wolny, M.,
Hoppe, U.C. (2017) clinical symptoms. Hyperpolarization-activated cyclic nucleotide channel 4 (HCN4) underlies the pacemaker
Yunusbaeva, M.,
Borodina, L.,
Alekseev, P.,
Davydov, R.,
Sharipov, R.,
Bilalov, F.,
Yunusbayev, B. (2019) recommendations. Altogether, 369 patients completed the full course of chemotherapy.
Clinical characteristics
Bulgakova, NA,
Vasilyeva, NA,
Imelbaeva, EA,
Shikova, YV,
Vasiliev, EA,
Salikhova, DI (2021) variety of
clinical manifestations, and a decrease in local or general factors of specific or nonspecific
Wu, JN,
Al-Zahrani, A,
Beylerli, O,
Sufianov, R,
Talybov, R,
Meshcheryakova, S,
Sufianova, G,
Gareev, I,
Sufianov, A (2022) circulating miR-155 and lower miR-181a/b and miR-410 expression is associated with
clinical data,
clinic blind randomized prospective one-center comparative placebo-controlled
clinical trial is carried out